🇺🇸 FDA
Patent

US 8815227

Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom

granted A61KA61K47/24A61K47/548

Quick answer

US patent 8815227 (Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom) held by Nektar Therapeutics expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K47/24, A61K47/548, A61K47/58, A61K47/60